

DAFTAR PUSTAKA

- Ahmad, T., Jackson, K., Rao, V. S., Tang, W. H. W., Brisco-Bacik, M. A., Chen, H. H., Felker, G. M., Hernandez, A. F., O'Connor, C. M., Sabbiseti, V. S., Bonventre, J. V., Wilson, F. P., Coca, S. G., & Testani, J. M. (2018). Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. *Circulation*, *137*(19), 2016–2028. <https://doi.org/10.1161/CIRCULATIONAHA.117.030112>
- Alvarez, A. M., & Mukherjee, D. (2011). Liver Abnormalities in Cardiac Diseases and Heart Failure. *The International Journal of Angiology : Official Publication of the International College of Angiology, Inc*, *20*(3), 135–142. <https://doi.org/10.1055/s-0031-1284434>
- Ariyachaipanich, A., R Kittayaphong, R, Kunjara Na Ayudhya, Yingchoncharoen T, Buakhamsri A, & Suvachittanon. (2019). Heart Failure Council of Thailand (HFCT) 2019 Heart Failure Guideline: Introduction and Diagnosis. *Journal of The Medical Association of Thailand*. [https://doi.org/J%2520Med%2520Assoc%2520Thai%25202019;102\(2\):231-9](https://doi.org/J%2520Med%2520Assoc%2520Thai%25202019;102(2):231-9)
- Arrigo, M., Jessup, M., Mullens, W., Reza, N., Shah, A. M., Sliwa, K., & Mebazaa, A. (2020). Acute heart failure. *Nature Reviews Disease Primers*, *6*(1), 16. <https://doi.org/10.1038/s41572-020-0151-7>
- Bankir, L., Bichet, D. G., & Morgenthaler, N. G. (2017). Vasopressin: Physiology, assessment and osmosensation. *Journal of Internal Medicine*, *282*(4), 284–297. <https://doi.org/10.1111/joim.12645>
- Bozkurt, B., & Kamat, I. S. (2019). Worsening Renal Function in Acute Decompensated Heart Failure: A Bad Sign or Maybe Not? *Transactions of the American Clinical and Climatological Association*, *130*, 41–50.
- Burchfield, J. S., Xie, M., & Hill, J. A. (2013). Pathological Ventricular Remodeling: Mechanisms: Part 1 of 2. *Circulation*, *128*(4), 388–400. <https://doi.org/10.1161/CIRCULATIONAHA.113.001878>
- Cavalcante, J. L., Khan, S., & Gheorghide, M. (2008). EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan. *Expert Review of Cardiovascular Therapy*, *6*(10), 1331–1338. <https://doi.org/10.1586/14779072.6.10.1331>
- Čerlinskaitė, K., Javanainen, T., Cinotti, R., Mebazaa, A., & on behalf of the Global Research on Acute Conditions Team (GREAT) Network. (2018). Acute Heart Failure Management. *Korean Circulation Journal*, *48*(6), 463. <https://doi.org/10.4070/kcj.2018.0125>
- Chirinos, J. A., Sardana, M., Oldland, G., Ansari, B., Lee, J., Hussain, A., Mustafa, A., Akers, S. R., Wei, W., Lakatta, E. G., & Fedorova, O. V. (2018). Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with

- and without heart failure. *ESC Heart Failure*, 5(5), 911–919.
<https://doi.org/10.1002/ehf2.12319>
- Chitturi, C., & Novak, J. E. (2018). Diuretics in the Management of Cardiorenal Syndrome. *Advances in Chronic Kidney Disease*, 25(5), 425–433.
<https://doi.org/10.1053/j.ackd.2018.08.008>
- Cyr, P. L., Slawsky, K. A., Olchanski, N., Krasa, H. B., Goss, T. F., Zimmer, C., & Hauptman, P. J. (2011). Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. *American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists*, 68(4), 328–333. <https://doi.org/10.2146/ajhp100217>
- Dev, S., Hoffman, T. K., Kavalieratos, D., Heidenreich, P., Wu, W., Schwenke, D. C., & Tracy, S. J. (2016). Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed-Methods Study. *Journal of the American Heart Association*, 5(3), e002493.
<https://doi.org/10.1161/JAHA.115.002493>
- Dickstein, K., Cohen-Solal, A., Filippatos, G., Authors/Task Force Members, McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., Van Veldhuisen, D. J., Atar, D., Hoes, A. W., Keren, A., Mebazaa, A., Nieminen, M., Priori, S. G., Swedberg, K., ESC Committee for Practice Guidelines (CPG), Vahanian, A., Camm, J., ... Zannad, F. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *European Heart Journal*, 29(19), 2388–2442.
<https://doi.org/10.1093/eurheartj/ehn309>
- Dixit, N. M., Shah, S., Ziaecian, B., Fonarow, G. C., & Hsu, J. J. (2021). Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization. *US Cardiology Review*, 15, e07. <https://doi.org/10.15420/usc.2020.29>
- Emmens, J. E., Ter Maaten, J. M., Matsue, Y., Figarska, S. M., Sama, I. E., Cotter, G., Cleland, J. G. F., Davison, B. A., Felker, G. M., Givertz, M. M., Greenberg, B., Pang, P. S., Severin, T., Gimpelewicz, C., Metra, M., Voors, A. A., & Teerlink, J. R. (2022). Worsening renal function in acute heart failure in the context of diuretic response. *European Journal of Heart Failure*, 24(2), 365–374. <https://doi.org/10.1002/ejhf.2384>
- Erdélyi, L. S., Hunyady, L., & Balla, A. (2023). V2 vasopressin receptor mutations: Future personalized therapy based on individual molecular biology. *Frontiers in Endocrinology*, 14, 1173601.
<https://doi.org/10.3389/fendo.2023.1173601>
- Farmakis, D., Papingiotis, G., & Parissis, J. (2017). Acute heart failure: Epidemiology and socioeconomic burden. *Continuing Cardiology Education*, 3(3), 88–92. <https://doi.org/10.1002/cce2.61>

- Faul, F., Erdfelder, E., Buchner, A., & Lang, A.-G. (2009). Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. *Behavior Research Methods*, 41(4), 1149–1160. <https://doi.org/10.3758/BRM.41.4.1149>
- Felker, G. M., Mentz, R. J., Cole, R. T., Adams, K. F., Egnaczyk, G. F., Fiuzat, M., Patel, C. B., Echols, M., Khouri, M. G., Tauras, J. M., Gupta, D., Monds, P., Roberts, R., & O'Connor, C. M. (2017). Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. *Journal of the American College of Cardiology*, 69(11), 1399–1406. <https://doi.org/10.1016/j.jacc.2016.09.004>
- Feola, M., Rossi, A., Testa, M., Ferreri, C., Palazzuoli, A., Pastorini, G., & Ruocco, G. (2020). Six-Month Predictive Value of Diuretic Resistance Formulas in Discharged Heart Failure Patients after an Acute Decompensation. *Journal of Clinical Medicine*, 9(9), 2932. <https://doi.org/10.3390/jcm9092932>
- Gheorghiad, M., Gattis, W. A., O'Connor, C. M., Adams, K. F., Elkayam, U., Barbagelata, A., Ghali, J. K., Benza, R. L., McGrew, F. A., Klapholz, M., Ouyang, J., Orlandi, C., & Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. (2004). Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. *JAMA*, 291(16), 1963–1971. <https://doi.org/10.1001/jama.291.16.1963>
- Gilotra, N. A. (2014). Arginine vasopressin as a target in the treatment of acute heart failure. *World Journal of Cardiology*, 6(12), 1252. <https://doi.org/10.4330/wjc.v6.i12.1252>
- Goldsmith, S. R. (2019). Arginine vasopressin antagonism in heart failure: Current status and possible new directions. *Journal of Cardiology*, 74(1), 49–52. <https://doi.org/10.1016/j.jjcc.2019.03.001>
- Goldsmith, S. R., Burkhoff, D., Gustafsson, F., Voors, A., Zannad, F., Kolkhof, P., Staedtler, G., Colorado, P., Dinh, W., & Udelson, J. E. (2021). Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. *Journal of Cardiac Failure*, 27(2), 233–241. <https://doi.org/10.1016/j.cardfail.2020.10.007>
- Gupta, R., Testani, J., & Collins, S. (2019). Diuretic Resistance in Heart Failure. *Current Heart Failure Reports*, 16(2), 57–66. <https://doi.org/10.1007/s11897-019-0424-1>
- Hanberg, J. S., Tang, W. H. W., Wilson, F. P., Coca, S. G., Ahmad, T., Brisco, M. A., & Testani, J. M. (2017). An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial. *International Journal of Cardiology*, 241, 277–282. <https://doi.org/10.1016/j.ijcard.2017.03.114>
- Haris, D. E., Rampengan, S. H., & Jim, E. L. (2016). Gambaran pasien gagal jantung akut yang menjalani rawat inap di RSUP Prof Dr. R. D. Kandou periode September-November 2016. *E-CliniC*, 4(2). <https://doi.org/10.35790/ecl.v4i2.14471>

- Harjola, V., Mullens, W., Banaszewski, M., Bauersachs, J., Brunner-La Rocca, H., Chioncel, O., Collins, S. P., Doehner, W., Filippatos, G. S., Flammer, A. J., Fuhrmann, V., Lainscak, M., Lassus, J., Legrand, M., Masip, J., Mueller, C., Papp, Z., Parissis, J., Platz, E., ... Mebazaa, A. (2017). Organ dysfunction, injury and failure in acute heart failure: From pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *European Journal of Heart Failure*, 19(7), 821–836. <https://doi.org/10.1002/ejhf.872>
- Hasanah, D. Y., Edrian Zulkarnain, Habibie Arifianto, Hawani Sasmaya, & Leonardo Paskah Suciadi. (2023). *Pedoman Tatalaksana Gagal Jantung* (3rd ed.). Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. <https://www.inaheart.org/storage/guideline/d4c92daca60a4c18c6d846209646c24e.pdf>
- Ishikawa, S. (2015). Hyponatremia Associated with Heart Failure: Pathological Role of Vasopressin-Dependent Impaired Water Excretion. *Journal of Clinical Medicine*, 4(5), 933–947. <https://doi.org/10.3390/jcm4050933>
- Ishikawa, S. (2017). Is Exaggerated Release of Arginine Vasopressin an Endocrine Disorder? Pathophysiology and Treatment. *Journal of Clinical Medicine*, 6(11), 102. <https://doi.org/10.3390/jcm6110102>
- Javaloyes, P., Miró, Ò., Gil, V., Martín-Sánchez, F. J., Jacob, J., Herrero, P., Takagi, K., Alquézar-Arbé, A., López Díez, M. P., Martín, E., Bibiano, C., Escoda, R., Gil, C., Fuentes, M., Llopis García, G., Álvarez Pérez, J. M., Jerez, A., Tost, J., Llauger, L., ... on behalf of the ICA-SEMES Research Group. (2019). Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. *European Journal of Heart Failure*, 21(11), 1353–1365. <https://doi.org/10.1002/ejhf.1502>
- Kansara, T., Gandhi, H., Majmundar, M., Kumar, A., Patel, J. A., Kokkiralala, A., Moskovits, N., Mushiyevev, S., & Basman, C. (2022). Tolvaptan add-on therapy and its effects on efficacy parameters and outcomes in patients hospitalized with heart failure. *Indian Heart Journal*, 74(1), 40–44. <https://doi.org/10.1016/j.ihj.2021.12.003>
- Kim, K.-J. (2021). Vasopressin Receptor Antagonist, Tolvaptan, for Treating Hyponatremia in Patients with Heart Failure. *Cardiovascular Prevention and Pharmacotherapy*, 3(1), 10. <https://doi.org/10.36011/cpp.2021.3.e3>
- Kiuchi, S., Hisatake, S., Kabuki, T., Oka, T., Dobashi, S., Fujii, T., & Ikeda, T. (2018). The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients. *Heart and Vessels*, 33(4), 367–373. <https://doi.org/10.1007/s00380-017-1067-3>
- Konstam, M. A. (2007). Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure The EVEREST Outcome Trial. *JAMA*, 297(12), 1319. <https://doi.org/10.1001/jama.297.12.1319>
- Kozhuharov, N., Goudev, A., Flores, D., Maeder, M. T., Walter, J., Shrestha, S., Gualandro, D. M., De Oliveira Junior, M. T., Sabti, Z., Müller, B.,

- Noveanu, M., Socrates, T., Ziller, R., Bayés-Genís, A., Sionis, A., Simon, P., Michou, E., Gujer, S., Gori, T., ... for the GALACTIC Investigators. (2019). Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial. *JAMA*, 322(23), 2292. <https://doi.org/10.1001/jama.2019.18598>
- Kumar, A., Iqbal, U., Amin, S. B., Arsal, S. A., Ali, S. M. S., Shafique, M. A., Shahid, M. S., Naz, A., & Asuka, E. S. (2025). Evaluating the safety and effectiveness of tolvaptan in patients with heart failure and renal impairment: A systematic review and meta-analysis. *European Journal of Clinical Pharmacology*, 81(2), 203–216. <https://doi.org/10.1007/s00228-024-03778-3>
- Kurmani, S., & Squire, I. (2017). Acute Heart Failure: Definition, Classification and Epidemiology. *Current Heart Failure Reports*, 14(5), 385–392. <https://doi.org/10.1007/s11897-017-0351-y>
- La Rovere, M. T., Pinna, G. D., & Raczak, G. (2008). Baroreflex Sensitivity: Measurement and Clinical Implications. *Annals of Noninvasive Electrocardiology*, 13(2), 191–207. <https://doi.org/10.1111/j.1542-474X.2008.00219.x>
- Lanfear, D. E., Sabbah, H. N., Goldsmith, S. R., Greene, S. J., Ambrosy, A. P., Fought, A. J., Kwasny, M. J., Swedberg, K., Yancy, C. W., Konstam, M. A., Maggioni, A. P., Zannad, F., & Gheorghiade, M. (2013). Association of Arginine Vasopressin Levels With Outcomes and the Effect of V2 Blockade in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights From the EVEREST Trial. *Circulation: Heart Failure*, 6(1), 47–52. <https://doi.org/10.1161/CIRCHEARTFAILURE.112.970012>
- Lawson, C. A., Testani, J. M., Mamas, M., Damman, K., Jones, P. W., Teece, L., & Kadam, U. T. (2018). Chronic kidney disease, worsening renal function and outcomes in a heart failure community setting: A UK national study. *International Journal of Cardiology*, 267, 120–127. <https://doi.org/10.1016/j.ijcard.2018.04.090>
- Leon, S. J., & Tangri, N. (2022). Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors/Mineralocorticoid Receptor Antagonists Blockade: It's Apples and Oranges. *Kidney360*, 3(8), 1442–1444. <https://doi.org/10.34067/KID.0000952022>
- Limkunakul, C., Srisantithum, B., Lerdrattanasakulchai, Y., Laksomya, T., Jungpanich, J., & Sawanyawisuth, K. (2021). Any heart failure treatments associated with worsening renal function in patients admitted due to acute heart failure? *Renal Failure*, 43(1), 123–127. <https://doi.org/10.1080/0886022X.2020.1858100>
- Lippi, G., & Sanchis-Gomar, F. (2020). Global epidemiology and future trends of heart failure. *AME Medical Journal*, 5, 15–15. <https://doi.org/10.21037/amj.2020.03.03>
- Liu, J., Sharma, N., Zheng, W., Ji, H., Tam, H., Wu, X., Manigrasso, M. B., Sandberg, K., & Verbalis, J. G. (2011). Sex differences in vasopressin V₂ receptor expression and vasopressin-induced antidiuresis. *American*

- Journal of Physiology-Renal Physiology*, 300(2), F433–F440.
<https://doi.org/10.1152/ajprenal.00199.2010>
- Lv, Q., Wu, Q., Yang, Y., Li, L., Ye, X., Wang, S., Lv, Y., Wang, M., & Li, Y. (2025). Comparative efficacy of different drugs in acute heart failure with renal dysfunction: A systematic review and network meta-analysis. *Frontiers in Cardiovascular Medicine*, 11, 1444068.
<https://doi.org/10.3389/fcvm.2024.1444068>
- Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., & Davis, L. L. (2024). 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. *Journal of the American College of Cardiology*, 83(15), 1445–1447.
- Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., Motiwala, S. R., Oliveros, E., Patterson, J. H., Walsh, M. N., Wasserman, A., Yancy, C. W., & Youmans, Q. R. (2021). 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. *Journal of the American College of Cardiology*, 77(6), 772–810.
<https://doi.org/10.1016/j.jacc.2020.11.022>
- Maisel, A. S., Krishnaswamy, P., Nowak, R. M., McCord, J., Hollander, J. E., Duc, P., Omland, T., Storrow, A. B., Abraham, W. T., Wu, A. H. B., Clopton, P., Steg, P. G., Westheim, A., Knudsen, C. W., Perez, A., Kazanegra, R., Herrmann, H. C., McCullough, P. A., & Breathing Not Properly Multinational Study Investigators. (2002). Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *The New England Journal of Medicine*, 347(3), 161–167.
<https://doi.org/10.1056/NEJMoa020233>
- Masella, C., Viggiano, D., Molfino, I., Zaccchia, M., Capolongo, G., Anastasio, P., & Simeoni, M. (2019). Diuretic Resistance in Cardio-Nephrology: Role of Pharmacokinetics, Hypochloremia, and Kidney Remodeling. *Kidney and Blood Pressure Research*, 44(5), 915–927.
<https://doi.org/10.1159/000502648>
- Matsue, Y., Suzuki, M., Torii, S., Yamaguchi, S., Fukamizu, S., Ono, Y., Fujii, H., Kitai, T., Nishioka, T., Sugi, K., Onishi, Y., Noda, M., Kagiya, N., Satoh, Y., Yoshida, K., & Goldsmith, S. R. (2016). Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. *Journal of Cardiac Failure*, 22(6), 423–432.
<https://doi.org/10.1016/j.cardfail.2016.02.007>
- McCoy, E. (2017). Understanding the Intention-to-treat Principle in Randomized Controlled Trials. *Western Journal of Emergency Medicine*, 18(6), 1075–1078. <https://doi.org/10.5811/westjem.2017.8.35985>
- McCullough, P. A., Mehta, H. S., Barker, C. M., Van Houten, J., Mollenkopf, S., Gunnarsson, C., Ryan, M., & Cork, D. P. (2021). Mortality and GUIDELINE-DIRECTED medical therapy in REAL-WORLD heart failure

- patients with reduced ejection fraction. *Clinical Cardiology*, 44(9), 1192–1198. <https://doi.org/10.1002/clc.23664>
- McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., ... Skibelund, A. K. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *European Heart Journal*, 42(36), 3599–3726. <https://doi.org/10.1093/eurheartj/ehab368>
- McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., De Boer, R. A., Desai, A. S., Diez, M., Drozd, J., Dukát, A., Ge, J., ... Langkilde, A.-M. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *New England Journal of Medicine*, 381(21), 1995–2008. <https://doi.org/10.1056/NEJMoa1911303>
- Newman, E., Kamanu, C., Gibson, G., & Brailovsky, Y. (2024). How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure. *Current Cardiology Reports*, 26(9), 995–1003. <https://doi.org/10.1007/s11886-024-02101-x>
- Nhat M, G., Hai H, N., & Ngoc-Hoa, C. (2020). Renal kinetics in acute heart failure. *Open Heart*, 7(1), e001173. <https://doi.org/10.1136/openhrt-2019-001173>
- Ohno, M. (2018). Renal congestion related to worsening renal function in patients with acute decompensated heart failure: Diuretic strategy for acute cardiorenal syndrome. *Archives of Clinical Nephrology*, 012–017. <https://doi.org/10.17352/acn.000031>
- Orso, D., Tavazzi, G., Corradi, F., Mearelli, F., Federici, N., Peric, D., D'Andrea, N., Santori, G., Mojoli, F., Forfori, F., Vetrugno, L., & Bove, T. (2021). Comparison of diuretic strategies in diuretic-resistant acute heart failure: A systematic review and network meta-analysis. *European Review for Medical and Pharmacological Sciences*, 25(7), 2971–2980. https://doi.org/10.26355/eurrev_202104_25550
- Pabel, S., Hamdani, N., Luedde, M., & Sossalla, S. (2021). SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelling? *Current Heart Failure Reports*, 18(5), 315–328. <https://doi.org/10.1007/s11897-021-00529-8>
- Pan, D., Pellicori, P., Dobbs, K., Bulemfu, J., Sokoreli, I., Urbinati, A., Brown, O., Sze, S., Rigby, A. S., Kazmi, S., Riistama, J. M., Cleland, J. G. F., & Clark, A. L. (2021). Prognostic value of the chest X-ray in patients hospitalised for heart failure. *Clinical Research in Cardiology*, 110(11), 1743–1756. <https://doi.org/10.1007/s00392-021-01836-9>
- Pandey, K. N. (2021). Molecular Signaling Mechanisms and Function of Natriuretic Peptide Receptor-A in the Pathophysiology of Cardiovascular Homeostasis. *Frontiers in Physiology*, 12, 693099. <https://doi.org/10.3389/fphys.2021.693099>

- Park, S.-H., & Kang, J. (2021). Worsening Renal Function during Acute Decompensated Heart Failure: A Bad Signal Never to Ignore. *International Journal of Heart Failure*, 3(2), 121. <https://doi.org/10.36628/ijhf.2021.0016>
- Parvez, Md. S., Rahman, M. A., Lita, A. I., Hossain, S., & Ahmed, M. U. (2021). Clinical Impact of Worsening Renal Function in Patients with Acute Decompensated Heart Failure. *Journal of Current Medical Research and Opinion*, 4(07), 983–994. <https://doi.org/10.15520/jcmro.v4i07.435>
- Petersen, J. W., & Felker, G. M. (2006). Inflammatory Biomarkers in Heart Failure. *Congestive Heart Failure*, 12(6), 324–328. <https://doi.org/10.1111/j.1527-5299.2006.05595.x>
- Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G. M. C., Ruilope, L. M., Ruschitzka, F., ... Van Der Meer, P. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal*, 37(27), 2129–2200. <https://doi.org/10.1093/eurheartj/ehw128>
- Pratama, V., Budiono, J., Thobari, J. A., Widyantoro, B., Anggraeni, V. Y., & Dinarti, L. K. (2024). The role of tolvaptan add-on therapy in patients with acute heart failure: A systematic review and network meta-analysis. *Frontiers in Cardiovascular Medicine*, 11, 1367442. <https://doi.org/10.3389/fcvm.2024.1367442>
- Raffaello, W. M., Henrina, J., Huang, I., Lim, M. A., Suciadi, L. P., Siswanto, B. B., & Pranata, R. (2020). Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes? *Cardiac Failure Review*, 7, e02. <https://doi.org/10.15420/cfr.2020.20>
- Rayner-Hartley, E., Virani, S., & Toma, M. (2018). Update on the management of acute heart failure. *Current Opinion in Cardiology*, 33(2), 225–231. <https://doi.org/10.1097/HCO.0000000000000485>
- Reyes, E. B., Ha, J.-W., Firdaus, I., Ghazi, A. M., Phrommintikul, A., Sim, D., Vu, Q. N., Siu, C. W., Yin, W.-H., & Cowie, M. R. (2016). Heart failure across Asia: Same healthcare burden but differences in organization of care. *International Journal of Cardiology*, 223, 163–167. <https://doi.org/10.1016/j.ijcard.2016.07.256>
- Roche Diagnostics. (2020). *UREAL*. Roche Diagnostics. https://labogids.sintmaria.be/sites/default/files/ureal_2020-01_v13_0.pdf
- Roche diagnostics. (2022). *ISE indirect Na-K-Cl for Gen.2*. Roche diagnostics. https://labogids.sintmaria.be/sites/default/files/ise_indirect_na-k-cl_2019-05_v11_6.pdf

- Roche Diagnostics. (2023). *Elecsys proBNP II*. Roche Diagnostic.
<https://assets.roche.com/f/173850/x/70a5170dde/elecsysprobnpii-07027664190-en-can.pdf>
- Rolski, F., & Maćzewski, M. (2025). Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors. *Pharmaceuticals*, 18(3), 313.
<https://doi.org/10.3390/ph18030313>
- Salahudeen, A. K., & Thajudeen, B. (2016). Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: Current data and future perspectives. *Cancer Management and Research, Volume 8*, 105–114. <https://doi.org/10.2147/CMAR.S90169>
- Shang, W., Zhang, Y., & Han, D. (2022). Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta-analysis. *Clinical Cardiology*, 45(10), 995–1001. <https://doi.org/10.1002/clc.23889>
- Shanmugam, E., Doss, C. R. M. P., George, M., Jena, A., Rajaram, M., Ramaraj, B., Anjaneyan, K., & Kanagesh, B. (2016). Effect of tolvaptan on acute heart failure with hyponatremia – A randomized, double blind, controlled clinical trial. *Indian Heart Journal*, 68, S15–S21.
<https://doi.org/10.1016/j.ihj.2015.07.006>
- Shirakabe, A., Hata, N., Kobayashi, N., Okazaki, H., Matsushita, M., Shibata, Y., Nishigoori, S., Uchiyama, S., Asai, K., & Shimizu, W. (2018). Worsening renal function definition is insufficient for evaluating acute renal failure in acute heart failure. *ESC Heart Failure*, 5(3), 322–331.
<https://doi.org/10.1002/ehf2.12264>
- Silva-Cardoso, J., Andrade, A., Brito, D., Ferreira, J., Fonseca, C., Peres, M., Franco, F., & Moura, B. (2021). SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction. *Revista Portuguesa de Cardiologia (English Edition)*, 40(9), 687–693.
<https://doi.org/10.1016/j.repce.2021.02.006>
- Simonavičius, J., Knackstedt, C., & Brunner-La Rocca, H.-P. (2019). Loop diuretics in chronic heart failure: How to manage congestion? *Heart Failure Reviews*, 24(1), 17–30. <https://doi.org/10.1007/s10741-018-9735-7>
- Sinnenberg, L., & Givertz, M. M. (2020). Acute heart failure. *Trends in Cardiovascular Medicine*, 30(2), 104–112.
<https://doi.org/10.1016/j.tcm.2019.03.007>
- Sullivan, R. D., Mehta, R. M., Tripathi, R., Reed, G. L., & Gladysheva, I. P. (2019). Renin Activity in Heart Failure with Reduced Systolic Function—New Insights. *International Journal of Molecular Sciences*, 20(13), 3182.
<https://doi.org/10.3390/ijms20133182>
- Suzuki, S., Kimura, K., Yoda, N., Fuchida, A., Kanzaki, Y., Maruyama, T., Hashizume, N., Kozuka, A., Motoki, H., Yahikozawa, K., & Kuwahara, K. (2024). Association of Early Tolvaptan Treatment and Length of In Hospital Stay in Elderly Patients with Acute Decompensated Heart Failure. *JMA Journal*, 7(4), 564–570. <https://doi.org/10.31662/jmaj.2024-0050>
- Szczepanska-Sadowska, E., Czarzasta, K., & Cudnoch-Jedrzejewska, A. (2018). Dysregulation of the Renin-Angiotensin System and the Vasopressinergic

- System Interactions in Cardiovascular Disorders. *Current Hypertension Reports*, 20(3), 19. <https://doi.org/10.1007/s11906-018-0823-9>
- Tang, J., Ye, L., Yan, Q., Zhang, X., & Wang, L. (2022). Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. *Frontiers in Pharmacology*, 13, 800490. <https://doi.org/10.3389/fphar.2022.800490>
- Ter Maaten, J. M., Martens, P., Damman, K., Dickstein, K., Ponikowski, P., Lang, C. C., Ng, L. L., Anker, S. D., Samani, N. J., Filippatos, G., Cleland, J. G., Zannad, F., Hillege, H. L., Van Veldhuisen, D. J., Metra, M., Voors, A. A., & Mullens, W. (2020). Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. *Clinical Research in Cardiology*, 109(8), 1048–1059. <https://doi.org/10.1007/s00392-020-01598-w>
- Testani, J. M., & Brisco-Bacik, M. A. (2017). Worsening Renal Function and Mortality in Heart Failure: Causality or Confounding? *Circulation: Heart Failure*, 10(2), e003835. <https://doi.org/10.1161/CIRCHEARTFAILURE.117.003835>
- Tim Riskesdas 2018. (2019). *Laporan Nasional Riskesdas 2018*. Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan. <https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/>
- Udelson, J. E., Bilsker, M., Hauptman, P. J., Sequeira, R., Thomas, I., O'Brien, T., Zimmer, C., Orlandi, C., & Konstam, M. A. (2011). A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Tolvaptan Monotherapy Compared to Furosemide and the Combination of Tolvaptan and Furosemide in Patients With Heart Failure and Systolic Dysfunction. *Journal of Cardiac Failure*, 17(12), 973–981. <https://doi.org/10.1016/j.cardfail.2011.08.005>
- Ural, D., Cavusoglu, Y., Eren, M., Karauzum, K., Temizhan, A., Yilmaz, M. B., Zoghi, M., Ramassubu, K., & Bozkurt, B. (2015). Diagnosis and management of acute heart failure. *The Anatolian Journal of Cardiology*, 15(11), 860–889. <https://doi.org/10.5152/AnatolJCardiol.2015.6567>
- Urbach, J., & Goldsmith, S. R. (2021). Vasopressin antagonism in heart failure: A review of the hemodynamic studies and major clinical trials. *Therapeutic Advances in Cardiovascular Disease*, 15, 1753944720977741. <https://doi.org/10.1177/1753944720977741>
- Vinod, P., Krishnappa, V., Chauvin, A. M., Khare, A., & Raina, R. (2017). Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure. *Cardiology Research*, 8(3), 87–95. <https://doi.org/10.14740/cr553w>
- Wu, M.-Y., Chen, T.-T., Chen, Y.-C., Tarng, D.-C., Wu, Y.-C., Lin, H.-H., & Tu, Y.-K. (2017). Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis. *PLOS ONE*, 12(9), e0184380. <https://doi.org/10.1371/journal.pone.0184380>
- Yamada, T., Ueyama, H., Chopra, N., Yamaji, T., Azushima, K., Kobayashi, R., Kinguchi, S., Urate, S., Suzuki, T., Abe, E., Saigusa, Y., Wakui, H.,

- Partridge, P., Burger, A., Bravo, C. A., Rodriguez, M. A., Ivey-Miranda, J., Tamura, K., Testani, J., & Coca, S. (2020). Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure. *Kidney International Reports*, 5(9), 1486–1494. <https://doi.org/10.1016/j.ekir.2020.06.031>
- Yamazaki, Y., Shiraishi, Y., Kohsaka, S., Nagatomo, Y., Fukuda, K., Kohno, T., & Yoshikawa, T. (2021). Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan. *Scientific Reports*, 11, 19360. <https://doi.org/10.1038/s41598-021-98173-8>
- Zeng, M., Li, N., Chen, T., Ti, Y., Zhang, C., & Bu, P. (2023). The Efficacy and Safety of Tolvaptan in Heart Failure Patients with Congestive Signs: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Cardiology Discovery*, 3(1), 30. <https://doi.org/10.1097/CD9.0000000000000061>